Singapore markets close in 1 hour 29 minutes

Lyell Immunopharma, Inc. (LYEL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.4500-0.0100 (-0.68%)
At close: 04:00PM EDT
1.4300 -0.02 (-1.38%)
After hours: 04:25PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 363.99M
Enterprise value -171.54M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)7.46
Price/book (mrq)0.49
Enterprise value/revenue -3.54
Enterprise value/EBITDA 0.90

Trading information

Stock price history

Beta (5Y monthly) -1.38
52-week change 3-79.23%
S&P500 52-week change 318.92%
52-week high 38.2450
52-week low 31.3900
50-day moving average 32.3215
200-day moving average 32.6839

Share statistics

Avg vol (3-month) 3709.44k
Avg vol (10-day) 3814.54k
Shares outstanding 5251.03M
Implied shares outstanding 6251.03M
Float 8160.33M
% held by insiders 115.72%
% held by institutions 168.50%
Shares short (30 Aug 2023) 422.07M
Short ratio (30 Aug 2023) 435.82
Short % of float (30 Aug 2023) 412.58%
Short % of shares outstanding (30 Aug 2023) 48.79%
Shares short (prior month 30 Jul 2023) 423.5M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Jun 2023


Profit margin 0.00%
Operating margin (ttm)-431.58%

Management effectiveness

Return on assets (ttm)-14.08%
Return on equity (ttm)-26.11%

Income statement

Revenue (ttm)48.48M
Revenue per share (ttm)0.19
Quarterly revenue growth (yoy)-99.90%
Gross profit (ttm)84.68M
EBITDA -189.48M
Net income avi to common (ttm)-209.5M
Diluted EPS (ttm)-0.8400
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)595.75M
Total cash per share (mrq)2.37
Total debt (mrq)66.07M
Total debt/equity (mrq)8.97%
Current ratio (mrq)17.63
Book value per share (mrq)2.93

Cash flow statement

Operating cash flow (ttm)-162.74M
Levered free cash flow (ttm)-74.99M